Healios K.K. (HLOSF)

Market Cap	318.73M +57.0%
Revenue (ttm)	663.32K -81.4%
Net Income	-14.14M
EPS	-0.13
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	1,262
Open	2.700
Previous Close	n/a
Day's Range	2.700 - 2.700
52-Week Range	1.900 - 4.450
Beta	1.54
RSI	50.11
Earnings Date	May 12, 2026

About Healios K.K.

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 65
• Stock Exchange: OTCMKTS
• Ticker Symbol: HLOSF

Financial Performance

In 2025, Healios K.K.'s revenue was 104.00 million, a decrease of -81.43% compared to the previous year's 560.00 million. Losses were -2.22 billion, -47.65% less than in 2024.

Financial numbers in JPY